Educational research only—not investment advice or a recommendation. Scores and estimates may use delayed, incomplete, restated, or corrected market and filing data. Independently verify information before making an investment decision.

Viatris Inc.

VTRSNASDAQ
Wall Street Score · overall investment15/100
$18.77USD+$0.05 (+0.27%)
Company website www.viatris.com
HeadquartersRobert J. Coury Global Center, Canonsburg, PA, 15317, US
Financial statement currencyUSD · no FX conversion applied
Healthcare · Drug Manufacturers - Specialty & Generic
Price from Oct 29, 2026Financials updated Oct 26, 2026
Explore stock sections · swipe left or right

VTRS · Price history

Price at last available close

$18.77

+$0.65 (+3.59%) 1M

2026-10-28

Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.

Advanced Chart

Company & revenue

About Viatris Inc.

Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.

Who they are

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs).

How they make money

Viatris operates a global healthcare platform that manufactures and markets a broad portfolio of generic and branded pharmaceutical products. The company generates revenue by leveraging its integrated supply chain, regulatory expertise, and commercial infrastructure to provide access to medicines across more than 10 major therapeutic areas worldwide.

Products & services

Viatris produces and sells a diverse range of pharmaceutical products, including complex generics, biosimilars, and established brands covering therapeutic areas such as cardiovascular health, oncology, infectious diseases, and immunology.

Brands & revenue mix

EpiPen

A well-known epinephrine auto-injector for the treatment of severe allergic reactions.

Separate brand revenue is not available in this research.Source

Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.

Product / operating segments

BrandsUSD 9.18B64.2%

Period ended 2025-12-31Source

GenericsUSD 5.07B35.4%

Period ended 2025-12-31Source

Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.

Geographic revenue

Developed Markets SegmentUSD 8.55B59.8%

Period ended 2025-12-31Source

Greater China SegmentUSD 2.33B16.3%

Period ended 2025-12-31Source

Emerging Markets SegmentUSD 2.22B15.5%

Period ended 2025-12-31Source

Japan, Australia and New Zealand SegmentUSD 1.20B8.4%

Period ended 2025-12-31Source

Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.

Customer types

Customer concentration

The company does not disclose specific customer concentration figures in its 2025 Form 10-K.

Suppliers, materials & equipment

  • Contract Manufacturing Organizations — The company utilizes various third-party contract manufacturers to support its global production network; specific supplier names are not disclosed.Source

Competitors

  • Teva Pharmaceutical Industries Ltd. — Competes in the global generic and specialty pharmaceutical markets.Source
  • Sandoz Group AG — Competes in the generic and biosimilar pharmaceutical sectors.Source

Strengths

  • Global manufacturing and supply chain infrastructureSource
  • Broad therapeutic portfolio across multiple geographiesSource

Risks

  • Intense price competition in the generic pharmaceutical industrySource
  • Regulatory and legal risks associated with manufacturing and product qualitySource

Sources

Company research sourceBrandsDeveloped Markets Segment

Wall Street Score

Overall investment score · Quality, value, risk and opportunity

15

Poor

PoorElite

View category scores →

Company Quality

How good is the actual business—regardless of today’s stock price?

18

Poor

Financial Strength

36

Business Quality / Moat

6

Management

0

Growth Quality

24

Risk / Durability

20

Weak Company · Expensive Stock

Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.

Opportunity

Opportunity Score · How does the current price compare with estimated value?

39

Avoid

Based on current valuation, company quality, recent trends, and available market signals.

View score details →

Model Outlook

12-month model · What does the model think happens next?

41/100

Building Historical Record

Model Score 41/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.

Probability unavailable — the model has not produced a calibrated probability yet.

Click for full breakdown →

WSS View

The quick read

The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.

At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.

The model outlook is currently cautious.

What we like
  • •Recent buyback activity is present
What to watch
  • •Elevated debt risk
  • •M&A headline · Oct 8, 2026
  • •Valuation is a weaker part of the current profile
  • •Revenue fundamentals are weak
  • •Asset quality is a weaker factor

Company-specific research

Questions worth answering for VTRS

Research inputs 100% complete

These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.

  • •Can VTRS maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
  • •Is VTRS's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
  • •Is VTRS's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • •What specifically needs to improve for VTRS to reach sustainable profitability?
  • •What future growth or profitability would be needed to justify VTRS's current valuation?
⚠ 2 warningsView warning details
Elevated debt riskM&A headline · Oct 8, 2026
Business analysis: 16 days ago · Fresh

Essential Investment Snapshot

Wall Street Score

15

0–100 · Poor

Opportunity Score

39

0–100 · Weak

Market Cap

$21.56B

P/E Ratio

-50.8

EPS

$-0.36

52-Week High

$18.75

52-Week Low

$9.92

Beta

0.86

Analyst Target

$20.00

Shares Outstanding

1.17B

Total Revenue

$14.74B

Total Debt

$13.63B

Dividend Yield (TTM)

2.56%

View dividend history

Liquidation Value / Share

$12.18

Estimated net asset value per share

Dividend / Share (TTM)

$0.48

Trailing 12 months by ex-date; not a forecast

Momentum & Volatility Signals

Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.

0–100 market signals
Momentum
68/ 100
-4 pts / 5d

Building upward momentum

5D +1.7% · 20D +5.9% · RSI 66 · Price vs 20D avg +4.4%
Volatility
22/ 100
-2 pts / 5d

Low movement

20D realized vol 27.6% · 60D 28.2% · Acceleration 0.98x
Momentum = Where is it going?

A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.

Volatility = How violently is it moving?

A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.

Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.

Notices for VTRS

Detected from reported data — verify before acting.

Dividend history reported

Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.

Historical repurchase activity

Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.

Elevated debt risk

Total debt is at least one year of revenue • Interest coverage is below 2x • Cash covers less than 20% of total debt

M&A headline · Oct 8, 2026

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.

PRNewsWire

Community Sentiment

0 active · 0 total calls
0% Bullish (0) 0% Bearish (0)

No personal call yet on VTRS.

Potential upside factors

  • +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
  • +Global manufacturing and supply chain infrastructure.
  • +Broad therapeutic portfolio across multiple geographies.
  • +Positive free cash flow may provide capacity to invest in growth.

Potential downside factors

  • −Debt risk (elevated): Total debt is at least one year of revenue.
  • −Interest coverage is below 2x.
  • −Cash covers less than 20% of total debt.
  • −Intense price competition in the generic pharmaceutical industry.

These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.

Create a free account to make a call.

Scores

Click any score for full breakdown
Wall Street Score
Very Weak15/ 100
Weak (0–50)Fair (51–71)Strong (72+)

Poor

15

Tap for breakdown →

Fair

50

Debt Cost3.2%
Debt Reduction YoY-2.8%
Debt / Equity1.00x

Tap for breakdown →

Poor

10

Revenue YoY3.1%
Revenue CAGR-3.7%
Net Margin-2.8%

Tap for breakdown →

Weak

47

Asset Growth YoY-10.4%
Liquidation/Share$12.18
Net Assets/MCap1.02x

Tap for breakdown →

Poor

8

Earnings Yield-2.0%
Buyback Yield1.2%
Debt Cost3.2%

Tap for breakdown →

Poor

0

ROIC-9.9%
ROE-2.9%
ROA-1.2%

Tap for breakdown →

Poor

6

EPS Growth—
FCF/Share Growth-2.7%
Rev/Share Growth-5.2%

Tap for breakdown →

Poor

0

Intrinsic Value—
Value Reference—
MOS—

Tap for breakdown →

Poor

23

Revenue10
Moat6
Valuation0

Tap for breakdown →

Poor

0

MOS %—
Value Reference—
Deep Discount Reference—

Tap for breakdown →

Poor

9

Interest Coverage-5.7x
ROIC-9.9%
FCF Yield9.2%

Tap for breakdown →

Poor

9

Financial9
Valuation0
Debt50

Tap for breakdown →

Poor

33

Survival Years0.3 yrs
Current Ratio1.30x
FCF Margin13.5%

Tap for breakdown →

Was this stock page easy to understand?

One click helps us improve the research experience. This is not tied to an investment decision.

Score Changes

3 historical score records available

Previous Score

15

Oct 1, 2026

Change

-0.1

points

Current Score

15

Oct 26, 2026

Category Changes

Revenue-0.1
Debt0
Assets-0.4
Capital0
Management0
Moat0
Valuation0
Buffett-0.1

VTRS decreased 0.1 points because some fundamentals weakened.

Projected Score

Projected Score

21

Projected Change

+6.4 points

Preliminary comparable-period financial changes suggest improvement of approximately 6.4 points. This is a projected estimate, not the official WallStreetScore.

Price vs. Value

Valuation unavailable

Current Price

$18.77

Model Intrinsic Value

—

Difference

—

Margin of Safety

—

Value Reference: —
Deep Discount Reference: —

Intrinsic value is not currently available for this stock, so valuation can't be calculated.

Financial Charts

Revenue

201420152016201720182019202020212022202320242025$0$4.5B$9.0B$13.5B$18.0B

Additional Metrics

Operating Cash Flow

201520172019202120232025$0$800M$1.6B$2.4B$3.2B

Total Debt

201520172019202120232025$0$7.0B$14.0B$21.0B$28.0B

Total Assets

201520172019202120232025$0$20.0B$40.0B$60.0B$80.0B

Net Margin %

No data
Monetary values in USD. Share counts in raw units.

Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.

Line ItemTTM2025202420232022202120202019201820172016
Revenue$14.74B$14.30B$14.74B$15.43B····························
Cost of Revenue$9.60B$9.29B$9.12B$8.99B····························
Gross Profit$5.13B$5.01B$5.62B$6.44B····························
Research & Development$1.02B$965.9M$808.7M$805.2M····························
SG&A Expenses$3.98B$3.79B$4.43B$4.65B····························
Operating Expenses$5.22B$7.68B$5.61B$5.67B····························
EBITDA$2.72B-$395.4M$2.64B$3.52B····························
Operating Income-$87.3M-$2.66B$10.1M$766.2M····························
Interest Expense$480.0M$471.3M$550.0M$573.1M····························
Income Before Tax-$662.2M-$3.67B-$623.2M$202.9M····························
Income Tax Expense-$251.5M-$150.1M$11.0M$148.2M····························
Net Income-$410.7M-$3.51B-$634.2M$54.7M····························
Basic EPS$-0.36$-3.00$-0.53$0.05····························
Basic Shares1.16B1.17B1.19B1.20B····························
Diluted Shares1.16B1.17B1.19B1.21B····························
Upgrade to Premium for up to 10 annual periods, where available.
Upgrade to Premium

Earnings Summary

Estimated earnings date:Nov 5, 2026
Estimated EPS: $0.64Estimated revenue: $3.79B
Jun 30, 2026Q2FY2026

Revenue

$3.76B

Estimate unavailable.

Revenue Beat/Miss

Not available (no estimate stored)

EPS

-$0.10

Estimate unavailable.

EPS Beat/Miss

Not available (no estimate stored)

Debt Change

-7.7%

Cash Change

+56.5%

Margin Change

-3.0 pp

Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.

Financial Changes Since Prior Period

What Improved

  • Cash position grew
  • Debt reduced

What Weakened

  • Margins contracted

Potential Score Impact

Positive indicators included revenue growth, EPS growth, cash levels, debt levels. Pressure indicators included net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.

Stored Earnings Analysis

Revenue increased 4.9%. EPS increased 2464.1%. Cash increased 56.5%. Total debt declined 7.7%. Net income margin declined by 3.0 percentage points.

Earnings-Call Transcript

Earnings-call transcript analysis is not currently available.

These results may influence future scores when the next evaluation is completed.

Upgrade to Premium to unlock all earnings history.View plans
Earnings data: 120 days ago · Stale

Insider Activity

Upgrade to unlock

Guru / Smart Money

Guru Score

38

Smart Money

38

Number of Gurus

3

Total Guru Value

Avg Portfolio Weight

Largest Holder

Largest Holder %

New Positions

Increased Positions

Reduced Positions

Exited Positions

Net Guru Sentiment

Upgrade to unlock

Short Interest

Upgrade to unlock
Government disclosed trading activity is available on the Smart Money directory. Filings may be delayed and may not represent complete current holdings.

Dividend History

Log in to view dividend history.

Conservative Projected Values

3 Years

$———.——

Premium

5 Years

$———.——

Premium

10 Years

$———.——

Premium

Conservative Projection Rate

——%

Premium

Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.

Conservative Projected Values

Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.

Start 7-Day Free Trial

Historical Outperformance Record

Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.

Start 7-Day Free Trial

Historical Trends

3 historical records
Jul 24, 26Oct 1, 26Oct 26, 260255075100

Historical Score Chart

3 of 3 records shown

Wall Street Score

Jul 24, 26Oct 1, 26Oct 26, 260255075100

Debt Score

Jul 24, 26Oct 1, 26Oct 26, 260255075100

Revenue Score

Jul 24, 26Oct 1, 26Oct 26, 260255075100

Asset Score

Jul 24, 26Oct 1, 26Oct 26, 260255075100

Capital Score

Jul 24, 26Oct 1, 26Oct 26, 260255075100

Management Score

Jul 24, 26Oct 1, 26Oct 26, 260255075100

Moat Score

Jul 24, 26Oct 1, 26Oct 26, 260255075100

Valuation Score

Jul 24, 26Oct 1, 26Oct 26, 260255075100

Buffett Score

Jul 24, 26Oct 1, 26Oct 26, 260255075100

Intrinsic Value

No data

Value Reference

No data

Margin of Safety %

No data

Related Companies

Drug Manufacturers - Specialty & Generic

CRON

Cronos Group Inc.

68Fair
$3.35View

ANIP

ANI Pharmaceuticals, Inc.

64Fair
$71.71View

AMPH

Amphastar Pharmaceuticals, Inc.

60Fair
$25.94View

LNTH

Lantheus Holdings, Inc.

58Fair
$100.10View

ZTS

Zoetis Inc.

58Fair
$77.80View

COLL

Collegium Pharmaceutical, Inc.

55Fair
$22.96View

News

Zacks Investment Research2d ago

Why Viatris (VTRS) is a Top Momentum Stock for the Long-Term

Zacks Investment Research8d ago

Here's Why Viatris (VTRS) is a Strong Value Stock

PRNewsWire12d ago

Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia

Business Wire16d ago

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

Rumor Mill · VTRS

Corporate developments & opportunities

Explore market →

Stocks in this report

PCRXPacira BioSciences, Inc.VTRSViatris Inc.
Confirmed announcementacquisition

Viatris agrees to acquire Pacira for $1.65 billion

Source date 2026-10-08

Viatris and Pacira announced a definitive acquisition agreement at $36.50 per Pacira share in cash, representing $1.65 billion in equity value. The proposed transaction adds Pacira’s EXPAREL and ZILRETTA pain therapies. Closing is expected by the end of 2026, subject to conditions.

Evidence score95/100

Strong source support

Potential impact

unknown

The agreement is confirmed; the acquisition has not closed. Research focus: tender participation, regulatory review, funding and integration. The $36.50 consideration is conditional transaction pricing, not a guaranteed future market price.

Viatris and Pacira ↗

Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.

Related Stock Research

Continue researching this company with related Wall Street Score rankings and investing guides.

Highest Wall Street Score stocksBest healthcare stocksHow Wall Street Score worksHow to analyze a stockUnderstanding financial healthIntrinsic value guide

Score Alerts

Premium unlocks alerts when a score rises, falls, or reaches your target price.

Start 7-Day Free Trial

Portfolio Score

Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.

Start 7-Day Free Trial